专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007065128A3 HUMAN ALPHA-DEFENSINS INHIBIT INTERLEUKIN-1BETA RELEASE 审中-公开
标题翻译：人类免疫缺陷抑制白细胞介素-1BETA释放
公开(公告)号：WO2007065128A3
公开(公告)日：2007-09-13
申请号：PCT/US2006061404
申请日：2006-11-30
申请人： UNIV AUBURN , SHI JISHU , AONO SHELLY , LU WUYUAN
发明人： SHI JISHU , AONO SHELLY , LU WUYUAN
IPC分类号： A61K38/17 , A61P29/00
CPC分类号： A61K38/1709
摘要： Human a-defensins are inhibitors of interleukin-lß post transitional processing and release. Interleukin-lß is a key cytokine involved in the initiation and amplification of the 5 inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1 (HNP-I) produced mainly by neutrophils, and human a-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-lß post transitional processing and release. Thus, a pharmaceutical composition and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical composition is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human a-defensins in a therapeutically effective amount or an amide, ester or salt thereof and a pharmaceutically effective carrier. The method for treating inflammation in mammalian tissues includes administering a human a-defensins to a mammal in an amount effective to inhibit the post translational processing and release of interleukin-lß.
摘要翻译：人类防御素是过渡性加工和释放后白介素-1β的抑制剂。白细胞介素-Iβ是涉及5种炎症过程的引发和扩增的关键细胞因子，包括诸如克罗恩病和溃疡性结肠炎等疾病的炎症。特别是主要由嗜中性粒细胞产生的人嗜中性粒细胞防御素-1（HNP-1），Paneth细胞产生的人α-防御素5（HD-5）已经被发现阻断了过渡性加工和释放后的白细胞介素-β。因此，本文公开了用于治疗哺乳动物组织中的炎症的药物组合物和方法。药物组合物是治疗性补充代谢途径以减少炎症，其包含治疗有效量的人α-防御素或其酰胺，酯或其盐和药学上有效的载体。用于治疗哺乳动物组织炎症的方法包括以有效抑制翻译后加工和释放白细胞介素-β的量向哺乳动物施用人α-防御素。

2. 发明申请

WO2020181197A1 TETRAMERIC PROTEIN SCAFFOLDS AS NANO-CARRIERS OF THERAPEUTIC PEPTIDES FOR TREATING CANCER AND OTHER DISEASES 审中-公开
公开(公告)号：WO2020181197A1
公开(公告)日：2020-09-10
申请号：PCT/US2020/021407
申请日：2020-03-06
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , LU, Wuyuan , MA, Bohan
发明人： LU, Wuyuan , MA, Bohan
IPC分类号： A61P35/00 , C07K14/82
摘要： A protein-based peptide drug carrier derived from the tetramerization domain of the chimeric oncogenic protein Bcr/Abl of chronic myeloid leukemia. Peptides to be delivered are grafted to the N-terminal helical region of Bcr/Abl tetramer. To facilitate cellular uptake, an Arg-repeating hexapeptide is added to the C-terminal end of the Bcr/Abl protein. The protein-based delivery strategy provides a clinically viable solution to p53-inspired anticancer therapy and is applicable to the development of many other peptide therapeutics to target other intracellular protein-protein interactions responsible for disease initiation and progression.

3. 发明申请

WO2007087557A2 SURFACE-LAYER PROTEIN COATED MICROSPHERES AND USES THEREOF 审中-公开
标题翻译：表面蛋白包被微球及其用途
公开(公告)号：WO2007087557A2
公开(公告)日：2007-08-02
申请号：PCT/US2007/060962
申请日：2007-01-24
申请人： UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE , DE LEEUW, Eric, P., H. , LU, Wuyuan
发明人： DE LEEUW, Eric, P., H. , LU, Wuyuan
IPC分类号： A61K31/138
CPC分类号： A61K31/138 , A61K9/5052 , A61K9/5068 , A61K38/164 , A61K38/1729 , A61K47/32 , A61K47/34 , Y02A50/475 , Y02A50/481
摘要： The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes methods of making and using the surface-layer protein coated microspheres of the invention for administering therapeutic agents to a subject in need thereof. The invention also includes pharmaceutical dosage units that include the surface-layer protein coated microspheres of the invention. The invention further includes various labeled defensins for use in the study of the properties and actions of defensins, and further includes the use of defensins, particularly HD5α in the treatment of inflammatory conditions of the bowel, such as Crohn's disease.
摘要翻译：本发明提供用于将治疗剂递送至肠的表面层蛋白质包被的微球体。这些表面层蛋白质包被的微球体通常包括由被表面层蛋白质包覆的微球体包封的核心。核心包括治疗剂，例如防卫素。本发明还包括制备和使用本发明的表面蛋白涂覆的微球体以将治疗剂施用于有需要的受试者的方法。本发明还包括药物剂量单位，其包括本发明的表面层蛋白包被的微球体。本发明进一步包括用于研究防御素的性质和作用的各种标记的防御素，并且还包括防御素，特别是HD5α在治疗肠炎性病症如克罗恩病中的用途。

4. 发明申请

WO2021091871A1 HIGH AFFINITY AND DUAL-SPECIFICITY PEPTIDE ANTAGONISTS OF MDM2 AND MDMX FOR P53 ACTIVATION 审中-公开
公开(公告)号：WO2021091871A1
公开(公告)日：2021-05-14
申请号：PCT/US2020/058669
申请日：2020-11-03
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , LU, Wuyuan , LI, Xiang
发明人： LU, Wuyuan , LI, Xiang
IPC分类号： A61K31/4745 , A61K47/64 , A61K47/69 , A61P35/00
摘要： Peptide antagonists of MDM2 and MDMX are disclosed. The peptide antagonists include antagonists of MDM2 or MDMX, as well as dual-specificity antagonists where the same peptide is an antagonist of both MDM2 and MDMX. The peptide antagonists have at least nanomolar binding affinity for MDM2 and/or MDMX, and in some cases picomolar binding affinity. The peptide antagonists can be used in methods based on blocking inhibition of p53 activity by MDM2 and/or MDMX. Such methods can be used in the treatment of diseases, such as cancer.

5. 发明申请

WO2015179657A1 TREATMENT OF CANCER AND INHIBITION OF METASTASIS USING HEMOGLOBIN BETA SUBUNIT 审中-公开
标题翻译：使用HEMOGLOBIN BETA SUBUNE治疗癌症和抑制肿瘤
公开(公告)号：WO2015179657A1
公开(公告)日：2015-11-26
申请号：PCT/US2015/031996
申请日：2015-05-21
申请人： LU, Wuyuan , WITZ, Isaac , MAMAN, Shelly , UNIVERSITY OF MARYLAND, BALTIMORE , RAMOT AT TEL-AVIV UNIVERSITY LTD.
发明人： LU, Wuyuan , WITZ, Isaac , MAMAN, Shelly
IPC分类号： G01N33/68 , G01N33/53 , G01N30/22 , G01N30/72 , A61K38/42 , A61P35/00
CPC分类号： A61K38/42 , A61K38/16 , A61K38/1709 , A61K47/48307 , C12N5/0693 , G01N30/22 , G01N30/72 , G01N30/88 , G01N33/53 , G01N33/57488 , G01N33/68 , G01N33/721 , G01N2030/8813
摘要： The beta 2 subunit of mouse hemoglobin (HBB2) has been identified as soluble factor from mouse lungs that exhibits cytostatic/cytotoxic activity against neuroblastoma lung micrometastases. The beta subunit of human hemoglobin (HBB) has been found to have similar activity. Methods of using these proteins and fragments thereof in the treatment of cancer and inhibition of metastasis are provided, along with methods of screening a subject for micrometastases by detecting HBB in a biological sample.
摘要翻译：小鼠血红蛋白（HBB2）的β2亚基已经被鉴定为对小鼠肺的可溶性因子，其对神经母细胞瘤肺微转移具有细胞抑制/细胞毒性活性。已发现人血红蛋白（HBB）的β亚基具有相似的活性。提供了将这些蛋白质及其片段用于治疗癌症和抑制转移的方法，以及通过检测生物样品中的HBB来筛选受试者的微转移的方法。

6. 发明申请

WO2009149339A3 P53 ACTIVATOR PEPTIDES 审中-公开
公开(公告)号：WO2009149339A3
公开(公告)日：2010-04-01
申请号：PCT/US2009046392
申请日：2009-06-05
申请人： UNIV MARYLAND , LU WUYUAN , ZELLA DAVIDE , LIU MIN , LI CHANGQING
发明人： LU WUYUAN , ZELLA DAVIDE , LIU MIN , LI CHANGQING
IPC分类号： C07K14/00 , C07K1/00 , C07K2/00 , C07K4/00 , C07K14/435 , C07K14/46 , C07K14/47
CPC分类号： C07K14/43522
摘要： The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical compositions of the present invention to a subject in need of treatment thereof.
摘要翻译：本发明涉及活化p53的新型多肽，以及编码这些p53活化肽的多核苷酸。本发明还涉及包含p53激活剂肽的药物组合物以及治疗异常病症如恶性肿瘤的方法，包括将本发明的药物组合物施用于需要治疗的受试者。

7. 发明申请

WO2009149339A2 P53 ACTIVATOR PEPTIDES 审中-公开
公开(公告)号：WO2009149339A2
公开(公告)日：2009-12-10
申请号：PCT/US2009/046392
申请日：2009-06-05
申请人： UNIVERSITY OF MARYLAND, BALTIMORE , LU, Wuyuan , ZELLA, Davide , LIU, Min , LI, Changqing
发明人： LU, Wuyuan , ZELLA, Davide , LIU, Min , LI, Changqing
IPC分类号： C07K14/00 , C07K2/00 , C07K4/00 , C07K1/00 , C07K14/435 , C07K14/46 , C07K14/47
CPC分类号： C07K14/43522
摘要： The present invention relates to novel polypeptides that activate p53, and the polynucleotides encoding these p53 activator peptides. The present invention also relates to pharmaceutical compositions comprising the p53 activator peptides as well as methods of treating abnormal conditions, such as malignant tumors, with the methods comprising administering the pharmaceutical compositions of the present invention to a subject in need of treatment thereof.
摘要翻译：本发明涉及活化p53的新型多肽，以及编码这些p53活化肽的多核苷酸。本发明还涉及包含p53激活剂肽的药物组合物以及治疗异常病症如恶性肿瘤的方法，包括将本发明的药物组合物施用于需要治疗的受试者。

8. 发明申请

WO2007087557A3 SURFACE-LAYER PROTEIN COATED MICROSPHERES AND USES THEREOF 审中-公开
标题翻译：表面层蛋白包被微胶囊及其用途
公开(公告)号：WO2007087557A3
公开(公告)日：2007-11-01
申请号：PCT/US2007060962
申请日：2007-01-24
申请人： UNIV MARYLAND BIOTECH INST , DE LEEUW ERIC P H , LU WUYUAN
发明人： DE LEEUW ERIC P H , LU WUYUAN
IPC分类号： A61K9/16
CPC分类号： A61K31/138 , A61K9/5052 , A61K9/5068 , A61K38/164 , A61K38/1729 , A61K47/32 , A61K47/34
摘要： The invention provides surface-layer protein coated microspheres for delivery of a therapeutic agent to the intestine. These surface-layer protein coated microspheres generally include a core encapsulated by a microsphere which is coated by surface layer protein. The core includes a therapeutic agent, such as a defensin. The invention also includes methods of making and using the surface-layer protein coated microspheres of the invention for administering therapeutic agents to a subject in need thereof. The invention also includes pharmaceutical dosage units that include the surface-layer protein coated microspheres of the invention. The invention further includes various labeled defensins for use in the study of the properties and actions of defensins, and further includes the use of defensins, particularly HD5a in the treatment of inflammatory conditions of the bowel, such as Crohn's disease.
摘要翻译：本发明提供了用于将治疗剂递送至肠的表面层蛋白质包被的微球。这些表面层蛋白质包被的微球通常包括由表面蛋白质包被的微球包裹的核心。核心包括治疗剂，如防御素。本发明还包括制备和使用本发明的表面层蛋白质包被的微球的方法，用于向有需要的受试者施用治疗剂。本发明还包括药物剂量单位，其包括本发明的表面层蛋白质包被的微球。本发明还包括用于研究防御素的性质和作用的各种标记的防御素，并且还包括使用防御素，特别是HD5a用于治疗肠炎症性疾病如克罗恩病。

9. 发明申请

WO2007065128A2 HUMAN ALPHA-DEFENSINS INHIBIT INTERLEUKIN-1BETA RELEASE 审中-公开
标题翻译：人类α-防御素抑制白细胞介素-1β释放
公开(公告)号：WO2007065128A2
公开(公告)日：2007-06-07
申请号：PCT/US2006/061404
申请日：2006-11-30
申请人： AUBURN UNIVERSITY , SHI, Jishu , AONO, Shelly , LU, Wuyuan
发明人： SHI, Jishu , AONO, Shelly , LU, Wuyuan
IPC分类号： A61K38/17 , A61P29/00
CPC分类号： A61K38/1709
摘要： Human α-defensins are inhibitors of interleukin-lβ post transitional processing and release. Interleukin-lβ is a key cytokine involved in the initiation and amplification of the 5 inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1 (HNP-I) produced mainly by neutrophils, and human α-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-lβ post transitional processing and release. Thus, a pharmaceutical composition and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical composition is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human α-defensins in a therapeutically effective amount or an amide, ester or salt thereof and a pharmaceutically effective carrier. The method for treating inflammation in mammalian tissues includes administering a human α-defensins to a mammal in an amount effective to inhibit the post translational processing and release of interleukin-lβ.
摘要翻译：人α-防御素是白细胞介素-1β过渡后加工和释放的抑制剂。白细胞介素-1β是参与启动和扩增炎性过程的关键细胞因子，包括克罗恩氏病和溃疡性结肠炎等疾病的炎症。特别是，已经发现主要由嗜中性粒细胞产生的人嗜中性粒细胞防御素-1（HNP-1）和由潘氏细胞产生的人α-防御素5（HD-5）阻断白细胞介素-1β在过渡后处理和释放。因此，本文公开了用于治疗哺乳动物组织中的炎症的药物组合物和方法。所述药物组合物是治疗性补充代谢途径以减轻炎症，所述炎症包含治疗有效量的人α-防御素或其酰胺，酯或盐以及药学上有效的载体。用于治疗哺乳动物组织炎症的方法包括以有效抑制白介素-1β的翻译后加工和释放的量向哺乳动物施用人α-防御素。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式